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1. Introduction 
Human immunodeficiency virus (HIV)-Associated Neurocognitive Disorders (HAND) 
define a wide spectrum of behavioral, cognitive and motor dysfunctions(Heaton, Clifford et 
al. ; Neuenburg, Brodt et al. 2002; McArthur 2004; Lindl, Marks et al. 2010). The initial 
criteria put forth by the American Association of Neurology described two levels of 
neurocognitive impairment in HIV (+) patients: HIV-associated dementia (HAD) and minor 
motor cognitive disorder (MCMD)(1996). However, the emergence of more subtle forms of 
cognitive impairment after the implementation of combination antiretroviral therapy 
(cART) in 1996 necessitated a revised classification, which now includes, in addition to 
HAD, asymptomatic neurocognitive impairment (ANI), and mild neurocognitive disorder 
(MND), while MCMD is no longer included in the classification (Antinori, Arendt et al. 
2007). While the incidence of HAD has declined in the cART era, from 10-15% to 
approximately 2%; ANI and MND have become more prevalent (Heaton, Clifford et al. 
2010). Overall, HAND continues to persist, affecting approximately 50% of HIV (+) patients 
in the cART era (Power, Boisse et al. 2009; Heaton, Clifford et al. 2010). The underlying 
neuropathology suggests a change from overt dementia to a more insidious neurocognitive 
impairment (Kusdra, McGuire et al. 2002; Anthony and Bell 2008; Everall, Vaida et al. 2009). 
Various factors, such as age-related vascular and metabolic changes and substance and 
alcohol abuse, the emergence of resistant virus species, persistent viral DNA in the central 
nervous system (CNS) despite successful plasma viral control, limited access of cART into 
the CNS, poor adherence to drug regimen, and possible cART-related neurotoxicities are 
suggested to contribute to these changes observed in the clinical and neuropathological 
presentation in the HAND brain. With the increased life expectancy, the ever-expanding 
repertoire of antiretroviral drugs (ARVs) and the patient-tailored, dynamic combination 
ARV regimens, the contribution of cART to the persistence of HAND is an urgent question 
that needs to be addressed to more successfully predict and prevent CNS related morbidity 
and mortality among HIV-infected patients.  
2. Clinical presentation of HAND 
HAND was initially characterized as a combination of acquired deficits in cognition and 
motor function, in addition to behavioral and emotional changes (Navia, Cho et al. 1986; 
www.intechopen.com
 
Recent Translational Research in HIV/AIDS 
 
296 
Portegies, Enting et al. 1993). When it became apparent that viral replication could not be 
controlled by the use of one or two antiretroviral drugs, and that the CNS was shown to 
provide a sanctuary for HIV (Brew, Pemberton et al. 1997; Pialoux, Fournier et al. 1997), 
more aggressive treatment plans employing multiple ARVs were implemented. Successful 
viral suppression due to cART led to the observed initial improvement in cognitive function 
and an overall decrease in the incidence of the most severe form of HAND, HAD. However, 
as patients are maintained on cART long-term, subtler forms of neurocognitive impairment, 
ANI and MND have since emerged (Power, Boisse et al. 2009; Heaton, Clifford et al. 2010). 
ANI is defined as mild neurocognitive impairment in the absence of a decline in activities of 
daily living (ADL), whereas mild-to moderate neurocognitive decline that affects ADL is 
considered MND. The areas of cognition affected include concentration and/or attention, 
executive functioning, memory, and visuospatial skills (Antinori, Arendt et al. 2007). 
Depression, psychosis and anxiety at varying severity are also commonly observed in HIV-
infected patients (Owe-Larsson, Sall et al. 2009). The complexity of cognitive and behavioral 
presentations in cART treated patients has served to obfuscate the underlying causes of 
these changes. 
The clinical course of disease progression of HAND has changed dramatically since the 
introduction of cART in 1996. In the pre-cART era, HIV-associated neurocognitive 
impairment tended to worsen over time, and was more likely to follow a fulminant course. 
In fact, when other risk factors were controlled for, HAD was associated with increased 
mortality (Ellis, Deutsch et al. 1997). In contrast, the neurocognitive symptoms associated 
with HIV appear to follow a more unpredictable course during the life-time of the patient in 
the cART era. While some patients may recover from MND with effective cART, others can 
worsen steadily with progression from ANI to HAD. Further yet, some patients might 
experience a fluctuating course (Cole, Margolick et al. 2007; Woods, Moore et al. 2009). 
However, while progression to HAD is still observed in a subset of patients, even though at 
a slower pace in most cases, the mortality is now less likely to associate with HAND, and 
more likely with co-existing factors, such as co-infections, substance and alcohol use, and 
age-related illnesses.  
3. Neuropathology of HAND 
HIV targets and leads to a selective loss of CD4+ T cells, which eventually causes the severe 
immunodeficiency that develops in cases of uncontrolled HIV infection. HIV also targets 
monocytes and macrophages early during infection, which enable HIV to establish viral 
reservoirs in the lymphoid tissue and the CNS (Gendelman, Lipton et al. 1994; Gonzalez-
Scarano and Martin-Garcia 2005; Kaul, Zheng et al. 2005). In fact, extensive in vitro and in 
vivo studies support the “Trojan Horse” model of HIV infection in the CNS (Liu, Lossinsky 
et al. 2002). According to this model, HIV enters the brain via infected monocytes that cross 
the blood-brain barrier (BBB). Once in the CNS, infected monocytes differentiate into 
macrophages, which then constitute viral reservoirs in the brain. A small number of neurons 
and glia may also become infected; however, such infection is not productive (Gendelman, 
Lipton et al. 1994; Gonzalez-Scarano and Martin-Garcia 2005; Kaul, Zheng et al. 2005).  
Two major mechanisms of neuronal damage have been proposed: 1) Direct neurotoxicity by 
viral proteins such as HIV envelope glycoprotein (gp120) and HIV transactivator of 
transcription (Tat) protein, and, 2) Indirect neurotoxicity induced by soluble factors released 
by infected and/or activated macrophages including, but not limited to, quinolinic acid, 
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TNF-, reactive oxygen species (ROS), and cytokines such as CXCL12 (stromal cell-derived 
factor-1, SDF-1), CCL2 (monocyte chemotactic protein-1, MCP-1), and interleukin-6 (IL-
6)(Price, Brew et al. 1988; Giulian, Yu et al. 1996; Soontornniyomkij, Nieto-Rodriguez et al. 
1998; Lindl, Marks et al. 2010). Most of these factors not only directly affect neurons but also 
induce the secretion of more of these and other neurotoxic soluble factors, such as excitatory 
amino acids such as glutamate from neighboring macrophages/microglia, and astrocytes 
(Gorry, Ong et al. 2003; Gonzalez-Scarano and Martin-Garcia 2005). In the chronic course of 
HIV infection, inflammatory events and oxidative stress that ensue in this environment in 
the CNS precipitate neuronal dysfunction and death. Several in vitro and in vivo studies lend 
support to the indirect mechanism of neurotoxicity. Increases in neuroinflammatory factors 
(e.g. TNF-, CCL2, and IL-6) have been detected in the cerebrospinal fluid (CSF) of HIV-
infected patients (Sippy, Hofman et al. 1995; Achim, Masliah et al. 1996; Achim and Wiley 
1996; Conant, Garzino-Demo et al. 1998; Gisolf, van Praag et al. 2000). Further, markers of 
oxidative stress, such as 4-hydroxynonenal (4-HNE), are well documented in HAND 
patients (Haughey, Cutler et al. 2004; Sacktor, Haughey et al. 2004). In addition, several 
studies have reported that neopterin and 2-microglobulin, regarded as indirect markers of 
macrophage activation, are elevated in the CSF of HIV infected patients (Yilmaz, Fuchs et al. 
2006; Edén, Fuchs et al. 2010; Hagberg, Cinque et al. 2010). Finally, the neuropathological 
correlates of inflammation, including astrocytosis and increased perivascular macrophage 
infiltration are commonly observed in the brains of HIV-infected patients (Kolson 2002; 
Kusdra, McGuire et al. 2002; Lindl, Marks et al. 2010).  
The precise mechanisms by which inflammation leads to neuronal death in response to 
these functionally diverse factors are not known; however, several mechanisms are likely 
candidates. Intracellular ROS accumulation can directly alter neuronal mitochondrial 
function, leading to neuronal damage and death (Reynolds, Laurie et al. 2007; Hu, Sheng et 
al. 2009). On the other hand, pro-inflammatory factors can impair glutamate reuptake by 
astrocytes (Gorry, Ong et al. 2003; Gonzalez-Scarano and Martin-Garcia 2005). Increased 
extracellular glutamate that is not buffered by astrocytes can activate N-methyl-D-aspartate 
glutamate (NMDA) receptors and lead to excess Ca2+ influx into the neurons (Giulian, Yu et 
al. 1996; O'Donnell, Agrawal et al. 2006). Much evidence indicates that increased 
intracellular Ca2+ concentrations are detrimental to neurons. Ca2+ can precipitate oxidative 
stress via free radical production, to which neurons are likely to become more susceptible in 
the absence of normal functioning astrocytes and macrophages. Further, excess intracellular 
Ca2+ activates the death-associated proteases, calpains and caspases (Moore, Rothwell et al. 
2002; Danial and Korsmeyer 2004). The pathological indicators of neuronal damage and 
death, dendritic simplification, axonal damage and synaptic loss, correlate best with the 
presence of infected macrophages and microglia (Masliah, Heaton et al. 1997; Ellis 2010). 
Interestingly, viral load (VL) does not correlate with neurodegeneration, suggesting that the 
indirect mechanisms might play a more important role in neuronal injury than the direct 
mechanisms (Tozzi, Balestra et al. 2007; Yilmaz, Price et al. 2008).  
Several CSF markers have been utilized in an attempt to predict, diagnose and monitor the 
progression of HAND. Among those, as markers of immune activation, TNF-, and CCL2 
levels were shown to correlate with neurological deficits in the pre-cART era (Gisolf, van 
Praag et al. 2000; Sevigny, Albert et al. 2004; Ragin, Wu et al. 2010); however, a more recent 
study did not show such a correlation for either of these markers among a cohort of patients 
on cART (McArthur, McDermott et al. 2004). Additionally, contrary to expectations, in 
patients on cART regimens with high predicted CSF concentrations, the markers of 
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inflammation and oxidative stress appear to persist (Roc, Ances et al. 2007). Further, while 
cART has been shown to decrease neopterin levels in the CSF, these levels still appear to be 
above those measured in uninfected individuals (Yilmaz, Fuchs et al. 2006). A recent study 
shows that the changes in CSF neopterin levels are not affected by ARVs with predicted 
high CSF concentrations (Eden and Fuchs 2010). These findings imply that neuroinflammation 
might be ongoing despite the success of cART in controlling viral replication; thus 
supplementary therapies that would alleviate inflammation appear necessary for a better 
control of HAND.  
4. HAND and Combination Antiretroviral Therapy 
The development of more sensitive reverse transcriptase polymerized chain reaction (RT-
PCR) methods for the detection of HIV RNA during the 1990s revealed that single ARV 
treatments were not able to completely suppress viral replication. It also became apparent 
that the development of ARV resistance was hampering the efforts to successfully 
suppress VL. These major concerns led to a revision in the treatment plan for HIV 
infection, which was initially called highly active antiretroviral therapy (HAART), and 
was later changed to combination antiretroviral therapy (cART). Currently recommended 
cART for ARV-naïve HIV-infected patients includes a cocktail of ARVs from three 
different classes, nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs/NtRTIs), 
non-nucleoside reverse-transcriptase inhibitors (nNRTIs), and protease inhibitors (PIs). 
Sustained viral suppression, improved immune function and better control of HIV-related 
co-morbidities have contributed to the reduction in HIV-associated morbidity and 
mortality in the era of cART.   
In addition to its success in the periphery, cART led to striking changes in the clinical 
presentation and disease progression of HAND. The incidence of frank HAD has decreased 
dramatically and HAND in the cART era follows a more protracted course. However, 
neurocognitive impairment still persists, albeit as a general rule it is not as severe as in the 
pre-cART era. Importantly, HAD patients on cART still exhibit increased levels of 
macrophage infiltration similar to those seen in patients with HAD in the pre-cART era. 
Virus-related factors, such as persistent viral DNA in the CNS despite successful 
suppression of plasma and CSF VL and the emergence of resistant virus species due to 
failure of ARV to reach therapeutically relevant concentrations in the CSF, likely account at 
least partially for these observations.  
Studies in animal models of HIV infection suggest that the seeding of HIV in the CNS can 
occur as early as 4 days after the initial exposure to the virus. In addition, HIV RNA can be 
detected in the human brain as early as 14 days after infection. These studies indicate that viral 
escape to the CNS during the initial phase of asymptomatic viremia is possible; thus early and 
sustained VL control is necessary to limit the establishment of an HIV reservoir in the CNS, 
which, as a consequence, would have an immediate impact on the development of HAND. 
However, the timing for cART initiation in ARV-naïve HIV-infected individuals is not 
straightforward due to serious systemic ARV-related side effects and potential non-adherence, 
which in itself carries increased risk for selection of drug-resistant virus strains. Based on data 
from large clinical trials revealing that the initial CD4 cell count is a major predictor of 
morbidity and mortality in HIV patients, The United States Panel on Antiretroviral Guidelines 
for Adults and Adolescents recommends that cART should be initiated in patients with CD4 
cell counts lower than 350 cells/l or in those with an AIDS-defining illness irrespective of 
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CD4 counts (Panel on Antiretroviral Guidelines for Adults and Adolescents. (Revised January 
10, 2011) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and 
adolescents, April 14, 2011, available from http://www.aidsinfo.nih.gov/ContentFiles/ 
AdultandAdolescentGL.pdf). cART is also recommended for patients with CD4 counts 
between 350-500 cells/l. The panel also states that cART should be considered irrespective of 
the CD4 counts in patients who have either HIV-associated nephropathy, or Hepatitis B 
infection that needs treatment. For those who have CD4 counts above 500, the panel was 
evenly divided, with 50% of the panel members voted in favor of starting cART, whereas the 
other 50% of members voted cART treatment as optional under these conditions. However, the 
panel has not reached consensus with regard to the time to start cART in the context of HAND 
risk reduction, an important factor in the persistence of HAND in the cART era. Unfortunately, 
even with early initiation of cART, failure of ARVs to reach effective CSF concentrations may 
hamper the suppression of VL in the CNS. Thus in an attempt to assess the efficacy with which 
ARVs reach effective CSF concentrations, a scoring system coined CNS penetrance 
effectiveness (CPE) scoring is being increasingly investigated in clinical studies (Letendre, 
Marquie-Beck et al. 2008; Marra, Zhao et al. 2009; Tozzi, Balestra et al. 2009; Edén, Fuchs et al. 
2010; Letendre, Ellis et al. 2010; Garvey, Winston et al. 2011; Smurzynski, Wu et al. 2011). An 
ARV drug with relatively poor CNS penetration is assigned a CPE score of 0, while one with 
an intermediate CNS penetration would have a CPE score of 0.5, and one with high 
penetration would receive a CPE score of 1. Each combination ARV treatment regimen 
includes ARVs from at least three different classes with distinct physicochemical properties 
and thus the sum of CPE scores from several types of drugs will affect the functional capacity 
of the regimen within the CNS. 
5. Antiretroviral drugs 
While each ARV is unique in structure, each ARV class has certain common characteristics 
that aid in determining the overall CPE score of any given cART. However, the unique 
properties of each drug also make it harder to accurately predict the CPE score for that 
particular ARV, and by extension, CPE score for specific cART regimens as well. For a better 
understanding of an ideal cART regimen for the control of HAND, we need to examine each 
ARV class. ARVs target HIV at distinct steps in the life cycle of the virus, including (1) virus 
attachment to the host cell, both fusion with the cell membrane and entry, (2) reverse 
transcription, (3) integration, (4) processing of viral proteins, and (5) maturation. The major 
classes of antiretroviral drugs are entry inhibitors, nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (nNRTIs), 
integrase inhibitors, and protease inhibitors (PIs). In this section, we will summarize the 
mechanisms of action, the general and CNS-specific side effects and the predictors of CPE 
scores for each class with the relevant in vitro and in vivo findings.  
5.1 Entry inhibitors 
HIV entry to the host cell begins with the binding of the HIV surface protein, gp120, to the T 
cell surface receptor CD4. This attachment exposes specific conserved regions of gp120, 
enabling its binding to one of the two chemokine receptors on the host cell surface, CXCR4 
or CCR5. This, in turn, unmasks gp41, a process that leads to the fusion of the viral 
membrane with the host cell and the subsequent release of the virus capsid into the host cell 
cytoplasm. This highly conserved, stepwise process provides three access points which a 
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relatively new class of ARVs, collectively termed entry inhibitors, targets. At this point, only 
two entry inhibitors are approved by the Food and Drug Administration (FDA) for clinical 
use: enfuvirtide (T-20), and maraviroc.  
5.1.1 Enfuvirtide 
Enfuvirtide is a 36 amino-acid synthetic peptide that mimics a specific region in gp41 and 
competitively inhibits the fusion step and does not depend on co-receptor use (Joly, Jidar et 
al. 2010). It is not a substrate for major drug metabolism enzymes, CYP3A4 or CYP2B6, a 
trait that limits possible interactions that might occur with other ARVs that are inhibitors or 
activators of these enzymes. Further, enfuvirtide acts in the extracellular area, and lacks 
cross-resistance. In addition, enfuvirtide-related side effects are minimal, and are usually 
limited to injection site reactions. Due to these characteristics, enfuvirtide is currently 
prescribed to ARV-experienced patients, especially those with multi-ARV resistance (Yeni, 
Mills et al. 2010). However, its potential benefits for patients with CNS involvement are not 
known. The only study where CNS penetrance of enfuvirtide was assessed in humans, has 
found CSF enfuvirtide levels to be below plasma EC50 (plasma concentration required for 
obtaining 50% of a maximum effect in vivo) values, which is most likely due to the high level 
of binding of enfuvirtide to plasma proteins (92%), mainly albumin (Patel, Zhang et al. 2005; 
Price, Parham et al. 2008). CSF concentration of a given pharmaceutical does not reflect its 
parenchymal concentration with certainty, as will be discussed in section 6; however, as 
extracellular enfuvirtide concentration determines its antiviral activity; its CSF levels most 
likely reflect its concentrations in the parenchyma. Based on these data, enfuvirtide is given 
a CPE score of zero (table 1 for proposed CPE scores of currently used ARVs) (Smurzynski, 
Wu et al. 2011). Importantly, a limited number of studies have found no association between 
the use of enfuvirtide and peripheral neuropathy, a side effect associated with certain ARVs. 
These findings, in addition to its low CPE score, likely preclude any potential neurotoxicity 
issues in the CNS related to enfuvirtide. In summary, the impact of enfuvirtide on HAND, 
whether beneficial or toxic, is most likely minimal; however, its efficacy in controlling 
systemic VL will certainly contribute to better control of disease progression in the CNS.  
5.1.2 Maraviroc 
The second clinically approved member of the entry inhibitor family is maraviroc. 
Maraviroc is a specific, non-competitive CCR5 antagonist and is effective in both ARV-naïve 
and ARV-experienced patients who harbor a CCR5-tropic virus, which is determined by 
genotypic and phenotypic tests before the initiation of maraviroc-including regimens 
(Lieberman-Blum, Fung et al. 2008; Kromdijk, Huitema et al. 2010). It is a substrate for drug 
efflux proteins ((p-glycoprotein (p-gp) and multidrug resistance protein-1 (MDR-1)) 
expressed by the BBB; however, its binding affinity to plasma proteins is not very high. 
Thus, CSF and brain distribution studies in rats suggest that approximately 10% of the 
plasma maraviroc levels are achieved in the CNS, which falls within a range of reported IC50 
(half maximal inhibitory concentration) values (Walker, Bowers et al. 2008). These 
predictions are further supported by multiple studies conducted in humans, where 
maraviroc achieves therapeutically relevant concentrations in the CSF, and also effectively 
suppresses CSF VL (table 1) (Smurzynski, Wu et al. 2011). Currently no data exists on the 
possible toxic effects of maraviroc in the CNS; however, given that the only cell types that 
express CCR5 are macrophages and T cells, direct neurotoxicity due to maraviroc is not 
likely. Thus, cART regimens that include maraviroc are increasingly prescribed and future 
studies are warranted to examine its impact on HAND.  
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Antiretroviral Class  CPE Score  
 1 0.5 0 
Entry Inhibitors   Enfuvirtide 
 Maraviroc   
Nucleoside/nucleotide 
reverse transcriptase 
inhibitors 
Zidovudine (AZT) Stavudine (d4T) Tenofovir (TDF) * 
 Abacavir (ABC) Lamivudine (3TC)  
  
Emtricitabine 
(FTC) * 
 
nNRTIs Nevirapine (NVP) Efavirenz (EFV)  
Protease Inhibitors Darunavir Amprenavir Nelfinavir 
  Atazanavir Ritonavir * 
  Fosamprenavir Saquinavir * 
  Indinavir  
Integrase Inhibitors  Raltegravir  
Table 1. CNS penetrance effectiveness (CPE) scores of antiretroviral drugs currently in 
clinical use. Higher CPE scores indicate better penetrance. * In vivo data suggests better CPE 
score 
5.2 Nucleoside/nucleotide reverse transcriptase inhibitors 
5.2.1 Mechanism 
The single-stranded HIV RNA, once in the host cell, is reverse transcribed by the viral 
reverse transcriptase (HIV-RT) into a double-stranded complementary viral DNA, which 
migrates to the host nucleus as part of the pre-integration complex. Nucleoside and 
nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) are analogues of the naturally 
occurring deoxynucleotides that are needed for the reverse-transcription (Warnke, Barreto 
et al. 2007); however, NRTIs/NtRTIs lack a 3'-hydroxyl group on the deoxyribose moiety. 
Three steps of phosphorylation are needed for NRTIs to become activated, while only two 
phosphorylation steps are necessary in the case of NtRTIs (Piliero 2004). Following 
activation, NRTIs/NtRTIs are incorporated into the viral DNA, thereby preventing the next 
5’-3’phosphodiester bond formation and consequently leading to the early termination of 
viral DNA synthesis, named chain termination (Warnke, Barreto et al. 2007).  
5.2.2 Clinical use 
NRTIs/NtRTIs quickly and effectively decrease VL and increase CD4 counts (Hill and 
Sawyer 2009). As they are not metabolized by drug metabolizing enzymes, the activities of 
which are altered by certain ARV drugs from other classes, dose adjustment is usually not 
necessary. Currently, five NRTIs (zidovudine (AZT), stavudine (d4T), lamivudine (3TC), 
emtricitabine (FTC), abacavir (ABC)) and one NtRTI (tenofovir disoproxil fumarate (TDF)) 
are used and form the backbone of most initial cART regimens. The current initial cART 
regimen typically includes two NRTIs/NtRTIs in addition to an nNRTI or a PI boosted with 
ritonavir, which is also a PI. The recently revised recommendations suggest that initial cART 
in ARV-naïve patients should include one of the following cocktails: 
efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC), ritonavir-boosted 
www.intechopen.com
 
Recent Translational Research in HIV/AIDS 
 
302 
atazanavir/tenofovir/emtricitabine (ATV+r/TDF/FTC), ritonavir-boosted 
darunavir/tenofovir/emtricitabine (DRV+r/TDF/FTC), or raltegravir + 
tenofovir/emtricitabine (RAL + TDF/FTC). A similar cART regimen is also recommended 
for post-exposure prophylaxis (Grant 2010). In addition, TDF/FTC cocktail is recommended 
as a pre-exposure prophylaxis regimen in high risk persons (Grant 2010). Further, 
combinations that include AZT, 3TC, and ABC are proven to be the most effective in 
prevention of intrauterine and postnatal transmission, with relatively few side effects to 
both mother and child, when compared with regimens that include nNRTIs or PIs (Sturt, 
Dokubo et al. 2010). However, specific NRTIs/NtRTIs are not considered part of a first line 
therapy in certain patient populations. For example, in pregnant women TDF is only 
considered when the infecting virus shows resistance to other NRTIs or in the presence of 
chronic hepatitis infection. This is due to concerns regarding possible toxicity of TDF for the 
fetus, specifically in bone mineralization (Duarte-Rojo and Heathcote 2010). Similarly, d4T 
can lead to sometimes fatal lactic acidosis and hepatic failure in pregnant women and is only 
used when no other viable options remain (Nolan and Mallal 2004).  
5.2.3 Side effects 
Due to the low fidelity of HIV-RT and to the high rate of HIV replication, NRTI/NtRTI-
resistant viral strains have developed. The emergence of these strains along with the severe 
NRTI/NtRTI-associated side effects, including lactic acidosis, lipoatrophy, and peripheral 
neuropathy, usually necessitates changes in the regimen, which can include switching 
ARVs, adding more ARVs, and/or adjusting dosing (Kohler and Lewis 2007). Interestingly, 
individual NRTIs/NtRTIs are associated with specific side effects. For example, d4T, and to 
a lesser extent, AZT, are associated with lipoatrophy, while TDF does not appear to cause 
this particular side effect. Peripheral neuropathy, which manifests in approximately 40% 
patients on cART, is associated with regimens that include d4T (Kohler and Lewis 2007). On 
the other hand, TDF is associated with increased risk of nephropathy and loss of bone 
density (Duarte-Rojo and Heathcote 2010). FTC-associated side effects are usually milder 
than those observed with other NRTIs/NtRTIs and include skin discoloration, nausea, and 
elevated liver enzymes (Nelson and Schiavone 2004).  
One major mechanism underlying NRTI/NtRTI-associated side effects is mitochondrial 
toxicity, which is a result of DNA polymerase inhibition, leading to mitochondrial DNA 
depletion, oxidative stress, loss of mitochondrial membrane potential (ΔΨm), and loss of 
oxidative phosphorylation (Dalakas 2001; Dagan, Sable et al. 2002; William 2003; Nolan and 
Mallal 2004). The potency of NRTIs in inhibiting DNA polymerase  differs among the 
members, with d4T and AZT showing higher potency compared with other NRTIs/NtRTIs. 
Further, the activities of the different kinases responsible for phosphorylation of each type of 
NRTI/NtRTI show variability among different cell types and may account for the cell-type 
specificity of the side effects (Bazzoli, Jullien et al. 2010).  
5.2.4 Considerations for the CNS 
Based on extensive data compiled from animal and human studies, AZT, d4T, and ABC 
appear to reach effective concentrations in the CNS, while the access of 3TC to the CNS is 
predicted to be minimal (Anderson and Rower 2010). There is limited information on TDF 
distribution in the CNS; the only functional study investigating TDF access to the CNS 
suggests that its concentrations in the CNS might be limited, with varying degrees of 
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accumulation in different brain regions (Anthonypillai, Gibbs et al. 2006). Currently, there is 
no information on CSF levels of FTC in the CSF (table 1) (Smurzynski, Wu et al. 2011). 
However, several reports suggest that regimens containing TDF and FTC may lead to 
improvements in neurocognitive impairment when compared with regimens that include 
other NRTIs or nNRTI/PIs (Allavena, Le Moal et al. 2006; Winston, Duncombe et al. 2010). 
Overall, clinical data from extensive studies show that NRTIs/NtRTIs, as part of cART 
regimens contribute significantly to the sharp decreases observed in the incidence of 
HAND. However, with regard to NRTIs/NtRTIs, several factors should be considered as 
possible contributors to the persistence of HAND. First, the emergence of NRTI/NtRTI 
resistance and possible less-than effective CSF concentrations, especially of 3TC and TDF, 
may limit their effectiveness in the eradication of the viral reservoirs in the CNS. In addition, 
mitochondrial toxicity due to NRTIs/NtRTIs may play a role in neuronal damage and 
death, as there is preliminary evidence that NRTIs may induce mitochondrial damage in 
neurons in vitro (Nolan and Mallal 2004). In conclusion, neurotoxicity as a result of 
prolonged exposure to NRTIs/NtRTIs should be monitored as a possible contributing factor 
to neurological deficits, especially since TDF and FTC are emerging as viable pre-exposure 
and post-exposure prophylaxis options. 
5.3 Non-nucleoside reverse transcriptase inhibitors 
5.3.1 Mechanism 
Like NRTIs/NtRTIs, nNRTIs block the conversion of the viral RNA genome to a double-
stranded DNA; however, the mechanism of action differs. nNRTIs bind to the allosteric, 
hydrophobic site of HIV RT, inhibiting its catalytic activity (de Bethune 2010). In addition, 
nNRTIs are not excised by pyrophosphates, which is a mechanism by which NRTI resistance 
can develop (de Bethune 2010). Thus, nNRTIs can circumvent certain NRTI-associated 
resistance mechanisms employed by the virus. However, it is now apparent that viral 
resistance to nNRTI still occurs, and has become a concern, especially in patients who are 
either ARV-experienced with previous exposure to nNRTIs or in those who are considered 
for nNRTI monotherapy. Further, there is an increased risk of cross-resistance development 
to NRTIs which can be triggered by the presence of nNRTI-associated mutations (de 
Bethune 2010). Thus, at least two NRTIs/NtRTIs need to be administered with nNRTIs, to 
achieve complete viral suppression and prevent resistance development. 
5.3.2 Clinical use 
Nevirapine (NVP), efavirenz (EFV) and etravirine (ETR) are the three nNRTIs currently 
approved for use. Efavirenz (EFV) is the nNRTI of choice in developed countries, whereas 
nevirapine (NVP) is included in initial cART regimens in resource limited countries. 
Additionally, NVP is used in the prevention of mother to child transfer, as EFV in pregnant 
patients is not recommended in the first trimester, due to the increased risk of neural tube 
defects associated with EFV (De Santis, Carducci et al. 2002). ETR is increasingly 
incorporated into cART regimens in recent years for treatment-experienced patients, as it 
maintains viral suppression in the presence of nNRTI-related resistance mutations, and has 
high tolerability with fewer side effects (de Bethune 2010).  
5.3.3 Side effects 
The side effects due to NVP include mild-to-moderate rash and hypersensitivity-induced 
hepatotoxicity, which can resolve spontaneously even when the therapy is continued (de 
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Bethune 2010). One major presentation of nNRTI related toxicity is neuropsychiatric 
disturbances. While NVP-induced CNS side effects, including impaired consciousness and 
psychotic episodes, have been rare, 40-70% patients on an EFV-containing cART regimen 
present with a range of CNS-related symptoms, such as insomnia, mood changes, and 
impaired attention span and concentration (Arendt, de Nocker et al. 2007).  
5.3.4 Considerations for the CNS 
While the exact mechanisms involved in EFV- and NVP-associated CNS side effects are not 
known, data from two recent studies have shown that chronic NVP or EFV administration 
in mice inhibited mitochondrial respiratory chain and creatine kinase activity in vivo (Streck, 
Scaini et al. 2008; Streck, Ferreira et al. 2011). As NVP and EFV show the highest CPE among 
all ARVs for which data is available (table 1), the changes in the energy metabolism these 
ARVs cause may affect particularly vulnerable cell populations in the brain, such as neurons 
with their high energy demands. Interestingly, a recent large scale study has shown that 
switching from an EFV containing cART to an ETR-based cART improved severe CNS side 
effects in ARV-experienced patients (Waters, Fisher et al. 2011). As will be mentioned in 
subsection 6.3, NVP and EFV are inducers of drug metabolism enzyme, CYP3A4, more so 
than ETR (Kakuda, Schöller-Gyüre et al. 2011), and may partially account for the partial 
alleviation in CNS-related side effects observed.  
5.4 Protease inhibitors 
5.4.1 Mechanism 
HIV protease inhibitors (PIs) are peptidomimetics, and inhibit viral proteases that are 
needed for virus maturation and assembly. Ten protease inhibitors are currently in use: 
indinavir, ritonavir, saquinavir, lopinavir, atazanavir, nelfinavir, amprenavir, 
fosamprenavir, tipranavir and darunavir. PIs have been shown to control plasma viral 
replication and improve immunological parameters as effectively as nNRTIs; thus they form 
an essential component of cART regimens across most patient populations (Warnke, Barreto 
et al. 2007). Several factors are taken into consideration when choosing a specific PI to be 
included in a cART regimen: prior use of ARVs, adherence and cost-effectiveness, pre-
existing conditions, and side effects are a few among these, and will be discussed below.  
5.4.2 Clinical use 
PIs are recommended for use with the NRTI/NtRTI backbone in initial cART regimens, just 
like nNRTIs (MacArthur, Novak et al. 2006). The decision between an nNRTI- and a PI-
based cART regimen depends on several factors, such as cardiovascular risks (insulin 
resistance, dyslipidemia), liver disease (hepatitis B and C included), pregnancy, 
neuropsychiatric disease risk/history, potential drug-drug interactions, and emergence of 
resistant virus. When PIs are included in the cART regimen, ritonavir is added to increase 
plasma concentrations of the first PI, as it is a potent inhibitor of CYP3A4, a major drug 
metabolizing enzyme (Xu and Desai 2009); the aim is better viral control and decreased 
resistance development. In order to decrease the pill burden and increase adherence, new 
drug formulations that include two PIs are used increasingly in clinical practice. The most 
commonly used PI combination is lopinavir/ritonavir, which is recommended for use 
during pregnancy as well as in pediatric HIV cases. On the other hand, all combinations 
other than saquinavir/ritonavir can be used in hepatitis B-and C-infected patients (Stephan, 
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Carlebach et al. 2007). It should be noted that the virological failure due to 
lopinavir/ritonavir containing regimens are less associated with the emergence of PI-
resistance (Prosperi, Zazzi et al. 2010), whereas nelfinavir has a lower barrier for PI-resistant 
virus emergence (Theys, Deforche et al. 2010). Lastly, regimens that include 
atazanavir/ritonavir and darunavir/ritonavir have less detrimental cardiovascular side 
effects compared with lopinavir/ritonavir-containing regimens (Hill, Sawyer et al. 2009). 
Thus, recently revised recommendations suggest atazanavir/ritonavir and 
darunavir/ritonavir as part of the initial cART regimen.  
5.4.3 Side effects 
Adverse effects associated with PIs are dyslipidemia, insulin resistance, and 
lipohypertrophy (Hui 2003). Numerous studies have shown that PIs alter lipid metabolism, 
and lead to dysregulation of blood lipid levels, which in itself increases risk of 
cardiovascular complications. Further, PIs induce oxidative and endoplasmic reticulum 
stress in macrophages, inducing these cells to release cytokines (CCL2, CCL3 (macrophage 
inflammatory protein-1, MIP-1), TNF- and IL-1) and ROS (Touzet and Philips 2010). 
These effects of PIs on macrophages are readily observed as increased risk for 
atherosclerosis and are more commonly associated with lopinavir/ritonavir-including 
regimens (Hill, Sawyer et al. 2009). 
5.4.4 Considerations for the CNS 
Most PIs, including ritonavir and saquinavir, are highly lipophilic and strongly bind to 
plasma proteins; thus, they are predicted to have low CSF concentrations (table 1). These 
predictions are backed by various in vitro and in vivo studies (Lledo-Garcia, Nacher et al. 
2007; Best, Letendre et al. 2009). However, a study conducted in an in situ guinea pig model 
suggests that ritonavir can achieve choroid plexus and parenchymal concentrations that are 
comparable to plasma levels, mainly by diffusion through the blood-choroid plexus barrier; 
interestingly CSF levels remain lower than those measured in the choroid plexus and the 
parenchymal compartments (Anthonypillai, Sanderson et al. 2004). Further, altered drug 
transport across the BBB due to viral proteins and neuroinflammation, in addition to a leaky 
BBB and blood-CSF barrier during the course of infection, can affect the actual CNS 
concentrations of ARVs. In the presence of a dysfunctioning BBB, PIs may induce indirect 
neuronal damage/death by triggering an inflammatory or oxidative stress response in 
macrophages in the CNS. Interestingly, one study has reported CNS-related side effects of 
PIs in an animal model where mice received ritonavir at doses comparable to those in cART 
regimens (Huisman, Smit et al. 2003). In that study, 2 out of 7 mice that received ritonavir 
co-administered with an inhibitor of the drug efflux protein p-gp developed the CNS-
specific symptoms, ataxia and tremor, before death one hour following treatment. Thus, 
long-term effects of PIs on CNS-specific toxicities warrant further investigation. 
5.5 Integrase inhibitors 
5.5.1 Mechanism 
Integrase inhibitors are a recently developed class of ARVs, which block the integrase 
enzyme that facilitates viral DNA integration into the host DNA. Currently, raltegravir is 
the only clinically approved drug of its class, and there are 3 more integrase inhibitors 
currently in different phases of clinical trials. 
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5.5.2 Clinical use and side effects 
The first clinical studies examining the efficacy and safety of raltegravir have shown that it 
facilitates viral suppression when added to the optimized regimens, even in patients with 
poor prognostic factors (Burger 2010). Further studies have shown that raltegravir efficacy 
was comparable to that of EFV when either drug is added to standard cART regimens 
(Powderly 2010; Steigbigel, Cooper et al. 2010). In addition, raltegravir is associated with 
few resistance mutations so far (Varghese, Liu et al. 2010), and its side effects are usually 
limited (Burger 2010). In fact, studies in rat hepatocytes in vitro and in mouse liver in vivo 
have suggested that the addition of raltegravir may inhibit PI-induced hepatotoxicity by 
blocking endoplasmic reticulum stress and lipid accumulation (Cao, Hu et al. 2010). Further, 
raltegravir does not appear to have an effect on drug metabolizing enzymes, which limits its 
possible drug-drug interactions. Thus, the FDA has now expanded its recommendations for 
raltegravir use in both ARV-naïve and ARV-experienced patients.  
5.5.3 Considerations for the CNS 
Raltegravir is a potential substrate of p-gp (Zembruski, Buchel et al. 2011), which would 
limit the entrance of this drug into the CNS. However, there are currently two clinical 
studies that have reported that raltegravir can achieve therapeutically relevant CSF 
concentrations (Yilmaz, Gisslen et al. 2009; Croteau, Letendre et al. 2010). Thus, raltegravir is 
given a CPE score of 0.5. While future studies are needed to determine its access to the CNS 
over the long-term, raltegravir appears to be a safe drug to use in the prevention and 
treatment of HAND, considering its minimal toxic effects in the periphery and its favorable 
CPE score, and that fewer viral resistance mutations hamper its efficacy. However, its long 
term effects on CNS specific cell populations are not known and caution should be exercised 
due to its high CPE score.  
6. Determinants of CNS drug penetrance 
The anatomical barriers between the CNS and the periphery are critical for protection of the 
brain from a multitude of factors; however, HIV appears to be able to circumvent these 
barriers. Early CNS seeding with HIV continues as a major obstacle in the efforts to 
eliminate the viral reservoirs throughout the body with the use of cART. In addition to the 
considerations regarding how long to delay the start of cART following infection, tailored 
cART regimens with better CNS penetrance, higher CSF ARV concentrations, and better 
parenchymal distribution are being increasingly sought after in an attempt to prevent and 
manage HAND. As the methodologies to determine the actual drug concentrations in the 
CSF and parenchyma of patients are not feasible, CPE algorithms are increasingly 
considered in determining which ARV drugs to include in a regimen to achieve 
therapeutically relevant CNS concentrations. Currently, the CPE score of a given ARV is 
based on the chemical structure, pharmacodynamics, pharmacokinetics, and available 
clinical correlative data (Letendre, Marquie-Beck et al. 2008; Marra, Zhao et al. 2009; 
Smurzynski, Wu et al. 2011). In this section, we will summarize the factors that determine 
the CPE score of ARVs in the presence of HAND. 
In general, for an ARV to have a high CPE score, it needs to be small in size (molecular mass 
below 400-500 kDa), with high lipid solubility and low protein binding, and it should not be 
a substrate for drug efflux or transport proteins, namely p-gp and multidrug resistance 
protein-1 (MRP-1). The integrity of the BBB, which HIV infection can compromise, should 
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also be considered in predicting CSF concentrations of ARVs. Also, due to the chronic 
nature of HIV infection, co-morbidities such as cancer, infections, and drug and alcohol 
abuse can also alter BBB integrity and should be considered as confounding factors in 
establishing effective and safe CPE algorithms.  
6.1 Blood-brain barrier 
The brain microvascular endothelial cells (BMVEC) within the brain parenchyma are the 
main constituents of the BBB. The BMVECs form an elaborate tight junction network, which, 
acts with the underlying basal lamina, pericytes, astrocyte foot processes, and microglia, to 
compose the BBB and to contribute to its function. A multitude of transporters and 
membrane proteins expressed by BMVECs regulate the cellular and molecular exchange 
between the CNS and the periphery, including the delivery of pharmaceuticals across the 
BBB into the brain parenchyma (Wolburg, Noell et al. 2009).  
The accumulation of serum proteins in the CSF and brain parenchyma of HAND patients 
indicates that BBB dysfunction occurs in these individuals (Roberts, Buckner et al. 2010). 
Both in vitro and in vivo studies have shown that the viral proteins, gp120 and Tat, can 
impair BBB integrity by induction of oxidative stress in BMVECs (Louboutin, Agrawal et al. 
2010). In addition, the disruption of tight junctions, loss of membrane glycoproteins, and 
apoptosis of BMVECs, as well as pericytic and perivascular astrocytic injury, have been 
reported following HIV infection (Persidsky, Stins et al. 1997). Given that predictions 
indicate that HIV-infected monocyte transmigration across the BBB will occur multiple 
times during the course of infection even with the successful control of peripheral VL (HIV 
RNA < 50 copies/ml), the continued assault on the BBB integrity in the presence of 
neuroinflammation is expected to exacerbate BBB dysfunction. Other factors that can 
increase the permeability of BBB are concomitant use of other pharmaceuticals for coexisting 
infections, substance and alcohol abuse, and co-infections.  
The basal ganglia, hippocampus, and frontal cortex are the regions that show the most 
striking evidence of neuroinflammation and neuronal damage in the HIV-infected brain. 
This regional preference of HAND correlates with the proximity of these structures to the 
BBB, the dysfunction of which has multiple implications in HAND pathogenesis, clinical 
course, and response to treatment. First, the breakdown of this natural barrier is likely to 
increase the recruitment of HIV-infected monocytes from the periphery, hampering the 
efforts to limit neuroinflammation. Further, the risk for secondary infections increases with 
compromised BBB integrity. Further, altered functions of drug efflux and transport proteins 
are likely to affect ARV penetrance into the CNS, and consequently increase the possibility 
of ARV-associated toxicities in this compartment. Thus, in situations where exacerbated BBB 
compromise is likely, such as substance use, cART regimens with the least CNS-specific 
toxicities should be considered. 
6.2 Drug transport across BBB 
Complex drug efflux and transport mechanisms, which are controlled by a number of 
proteins that are expressed mainly on the BMVEC membrane, ultimately determine the 
effectiveness of any given ARV in gaining access to the CNS. P-gp and MRP-1 are the two 
major and well-characterized members of this regulatory mechanism. P-gp is a membrane 
bound, ATP-dependant drug efflux pump and regulates concentration-time profiles of its 
substrates, which range from amphipathic lipid-soluble compounds and metabolites to 
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certain classes of ARVs, including most PIs and raltegravir (Urquhart and Kim 2009). PIs are 
both substrates and inhibitors of p-gp, while raltegravir appears to be a substrate but not an 
inhibitor of p-gp (Huisman, Smit et al. 2000). Ritonavir and saquinavir are the most 
extensively evaluated PIs in this regard. Findings from in vitro and in vivo studies show that 
p-gp limits the permeability of both ritonavir and saquinavir across the BBB. Interestingly, 
these drugs increase the expression of p-gp as well (Huisman, Smit et al. 2000). Ritonavir is 
added to most cART regimens in both ARV-naïve and ARV-experienced patients in order to 
exploit its ability to boost plasma concentrations of other ARVs (Xu and Desai 2009). 
However, the ability of ritonavir to increase the expression of p-gp can limit CNS access of 
concomitantly administered ARVs that are also p-gp substrates. Further, HIV infection can 
increase p-gp expression in T cells and monocytic cell lines and this capacity may extend to 
other cell-types, further contributing to the limited penetrance of ARVs to the CNS (Zhong, 
Hennig et al. 2010). 
MRP-1 provides an additional level of regulation of drug concentrations in the CNS. This 
BBB-resident protein mainly transports neutral drugs conjugated to glutathione, sulfate, or 
glucuronate, in addition to negatively charged anionic drugs and organic anionic drugs 
(Dallas, Miller et al. 2006). Numerous in vitro and in vivo studies show that PIs, as well as a 
number of NRTIs and nNRTIs, can inhibit MRP-1 function. A recent study reports that two 
NRTIs included in the recommended cART regimens, TDF and FTC, as well as the two most 
commonly used nNRTIs, EFV and NVP, can inhibit MRP-1 in a concentration-dependent 
manner in vitro (Weiss, Theile et al. 2007). Further, while TDF concentration in the CSF is 
limited, as measured in patient samples (Anthonypillai, Gibbs et al. 2006), clinical data show 
that TDF or FTC-including regimens are associated with better neurological outcomes 
(Winston, Duncombe et al. 2010), suggesting that the effect of cART on MRP-1 can influence 
the outcomes of antiretroviral therapy in the CNS.  
6.3 Pharmacokinetics 
In the liver, where the majority of drug metabolism occurs via the Cytochrome P450 (CYP) 
family of enzymes, Cytochrome P450 3A4 (CYP3A4) is the major enzyme that metabolizes 
the vast majority of drugs, including ARVs (Lakhman, Ma et al. 2009). Conversely, some 
drugs, including ARVs can enhance or inhibit the activity of CYP3A4 and can precipitate 
decreased drug efficacy or increased drug concentrations and toxicity, respectively, when 
added to the existing treatment plan (Fichtenbaum and Gerber 2002). For example, several 
non-ARV drugs prescribed concurrently with ARVs for co-existing conditions, such as 
macrolide antibiotics, cholesterol-lowering drugs, and calcium channel blockers, are 
CYP3A4 inhibitors, as is ritonavir. The addition of one of the aforementioned non-ARV 
drugs to a cART regimen that already includes ritonavir necessitates the lowering of ARV 
doses. EFV and NVP, on the other hand are strong inducers of CYP3A4, further 
complicating treatment strategies (Mugundu, Hariparsad et al. 2010). Data from a guinea 
pig model of drug diffusion showed that NVP limited CSF distribution of ritonavir 
(Anthonypillai, Sanderson et al. 2004). This example further highlights the importance of 
drug-drug interactions in determining the CPE score of a cART regimen. 
Intriguingly, CYP2B6, another member of the CYP family, is also induced by EFV and NVP 
(Ngaimisi, Mugusi et al. 2010). CYP2B6 is expressed in a number of extrahepatic tissues in 
addition to the liver, including the neurons and astrocytes of the different brain regions 
(Wang and Tompkins 2008). Thus, the predicted concentrations of drugs that are CYP2B6 
substrates in the CNS can be compounded by the concurrent use of EFV or NVP. On the 
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other hand, the activity of CYP2B6 varies widely among individuals due to the common 
occurrence of SNPs (Elens, Vandercam et al. 2010), as well as its transcriptional regulation 
(Wang and Tompkins 2008), and pharmacogenomic profiling may be necessary for 
successful dosing for regimens that include EFV and NVP. 
In summary, the factors discussed in this section contribute to the CPE scoring and provide 
a starting point for clinicians for devising the most effective cART regimen to control 
HAND. However, dose adjustments and drug replacements have become a necessary part 
of the treatment plans while trying to find a balance between maximum efficiency and 
minimum side effects. At the present, the implications of these changes during the long 
course of HIV infection are not known; however, several clinical studies suggest that 
insufficient suppression of CSF VL, which can arise from fluctuations in the CSF ARV 
concentrations, is associated with treatment failure, i.e. emergence of resistant virus, 
worsening of neurological symptoms. Thus, utmost effort should be made to minimize such 
fluctuations in order to decrease the prevalence of HAND. 
7. The impact of CPE scores on HAND 
To date, six studies have investigated the effectiveness of CPE scoring in the prevention and 
management of HAND (Letendre, Marquie-Beck et al. 2008; Cysique, Vaida et al. 2009; 
Marra, Zhao et al. 2009; Garvey, Winston et al. 2011; Lanoy, Guiguet et al. 2011; Smurzynski, 
Wu et al. 2011). The most important conclusion these studies suggest is that the use of ARVs 
with high CPE scores is beneficial for suppressing CSF HIV RNA levels and for improving 
neurocognitive deficits. Further, this correlation between CPE scores and neurological 
improvements is independent of the success of the given regimen at suppressing peripheral 
VL. Interestingly, data suggest that ARV-naive patients show better improvement in 
neurocognitive deficits than ARV-experienced patients, likely due to the existence of drug-
resistant virus harbored by the latter group.  
While the majority of these studies have found a positive correlation between CPE scores 
and neurological outcomes, a study by Marra et al. reported that cART regimens with higher 
CPE scores were associated with worse neurocognitive performance (Marra, Zhao et al. 
2009). The authors argued that this result was most likely due to the small size of the cohort 
and a possible bias towards prescription of more CPE penetrant regimens to patients with 
worse baseline neurocognitive impairment. However, cART regimens with higher CPE 
scores carry a risk of neurotoxicity in the already compromised brains of patients.  
There are surprisingly few animal studies that investigated CNS-specific side effects of 
ARVs; however, findings suggest that NVP and EFV can induce cognitive deficits and 
anxiety when administered at doses that are reflective of doses used in humans over a short 
term (Streck, Scaini et al. 2008; Streck, Ferreira et al. 2011). The underlying mechanisms of 
NVP or EFV-induced CNS side effects are not known but given that these ARVs can achieve 
therapeutically relevant concentrations in the CNS, the long-term exposure to these ARVs 
may contribute to the persistence of HAND despite successful control of VL and further 
investigation is warranted.  
Interestingly, one study has reported that ritonavir can induce acute signs of CNS-related 
toxicity, including ataxia and tremor in mice followed by death within an hour, when it is 
administered in the presence of a p-gp inhibitor (Huisman, Smit et al. 2003). These data 
suggests that acute exposure to high doses of ritonavir might be neurotoxic. In addition, mice 
that were administered lopinavir/ritonavir for 3 weeks at clinically relevant doses showed 
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significant cognitive impairment, as determined by a multi-unit T-maze (Pistell, Gupta et al. 
2010). Further, PIs cause increases in inflammatory markers via oxidative and endoplasmic 
reticulum stress response of macrophages (Touzet and Philips 2010). Thus, some of the CNS-
related toxicities observed in animal models might be a result of activated macrophages by 
these ARVs. In the presence of a neuroinflammatory environment, the recruitment ARV-
activated macrophages from the periphery in the presence of a compromised BBB can 
potentiate indirect neurotoxicity due to these ARVs. In addition, as mentioned in section 5.4, 
ritonavir concentrations in the brain parenchyma might be higher than predicted by the 
classical determinants of CPE (Anthonypillai, Sanderson et al. 2004), and direct neurotoxicity 
via oxidative stress can further precipitate neuronal damage and death. 
In summary, in a setting where long-term administration of cART is inevitable to control 
infection and as a prophylactic measure, animal studies which better represent the 
inflammatory conditions observed in HIV-infected brain are needed to more successfully 
predict the CPE scores of ARVs and determine the most efficient combinations with 
minimal CNS related toxicities. Further, large-scale, longitudinal studies will be 
instrumental to tease out the contribution of ARV-related neurotoxicities to the persistence 
of HAND.  
8. CNS-specific co-morbidities and cART effectiveness 
Since its inception, cART has changed the landscape of HIV infection. However, it has also 
introduced unique challenges in the management of HIV. Due to longer life expectancy, co-
morbidities such as substance abuse, chronic co-infections, and aging have become major 
contributors to HAND development and persistence. These co-morbidities need to be taken 
into consideration when cART regimens are determined on a patient-by-patient base. 
8.1 Drugs of abuse 
Perhaps the most important HIV associated co-morbidity is illicit drug use. For example, 
HIV-infected patients using methamphetamine (METH) show more neurocognitive deficits, 
compared to those not using METH (Nath 2010). These findings are not surprising, as illicit 
drugs, such as morphine and methamphetamine, alter the BBB permeability through direct 
damage to the BMVECs (Ramirez, Potula et al. 2009). In addition, these drugs exert 
neurotoxic effects in the CNS through oxidative stress and mitochondrial dysfunction 
(Yamamoto, Moszczynska et al. 2010). As mentioned in previous sections, BBB dysfunction 
and neurotoxicity are observed during the course of HIV infection as well as in response to 
ARV exposure and include similar mechanisms. Considering that the prevalence of HIV 
infection is 12-17% among illicit drug users (Cadet and Krasnova 2007), animal and clinical 
studies are essential to tailor cART regimens that reach sufficient CSF concentrations and yet 
do not augment neurotoxicity that might already be occuring in response to drug abuse.  
8.2 Chronic alcohol use 
A second co-morbidity that needs to be considered in the era of cART is chronic alcohol use. 
Chronic alcohol consumption has been established as a major confounding factor in the 
development of HAND (Durazzo, Rothlind et al. 2007; Miguez-Burbano, Lewis et al. 2008; 
Miguez-Burbano, Nair et al. 2009). Extensive studies have shown that chronic ethanol 
exposure causes neuronal damage and death (Brust 2010). Further, ethanol directly damages 
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the BBB structure, and elicits a pro-inflammatory response in the parenchyma, as detected 
by increases in CCL2 and IL1-, and increased ROS accumulation in the hippocampus(Shiu, 
Barbier et al. 2007; Qin, He et al. 2008). These effects are expected to be augmented in the 
presence of HIV infection. Further, ARV-induced neurotoxicity due to loss of BBB integrity 
in the setting of neuroinflammation is a possibility over the long term. Finally, chronic 
alcohol use will impair adherence to cART regimens. Thus, chronic alcohol use remains an 
important obstacle in the eradication of HAND. 
8.3 Co-infections 
The possible CNS-related effects of co-infections also need to be considered in HIV-infected 
population. Hepatitis B and C (HBV and HCV) were major co-morbidity and mortality 
factors in the pre-cART era. cART not only improved immunological functions, altering the 
detrimental effects of these viruses on the immune system, but also helped control the 
hepatitis virus replication to a certain extent. However, mortality due to liver disease 
remains the second most common following AIDS-related deaths. Recent data from Anti-
HIV study group (D:A:D) revealed that, of all the deaths that are due to liver disease, 66% 
were a result of HCV, while 17% was due to HBV, and 3% was related to cART-related 
hepatotoxicity (Turner, Bansi et al. 2010). While these viruses do not target the cells of the 
CNS and there is no direct evidence of hepatitis as a contributing factor for the persistence 
of HAND; there is evidence that viral suppression and CD4 cell recovery is not as successful 
in the presence of HCV or HBV. These findings might partially explain the sporadic data 
suggesting that worse neurocognitive impairment is observed in HIV-HCV co-infected 
patients (Winston, Duncombe et al. 2010).  
8.4 Aging 
The contribution of cART to the increased life span of HIV-infected individuals cannot be 
overstated. However, longer life expectancy has brought new complications to the 
management of disease, one of which is the age-related metabolic and functional changes in 
the CNS. The neuroinflammation is still observed in the hippocampus of patients with 
suppressed CNS and peripheral VL, in addition to the accumulation of phosphorylated Tau, 
and intracellular and extracellular -amyloid (A) in the frontal cortex and the 
hippocampus(Brew, Pemberton et al. 2005; Green, Masliah et al. 2005; Anthony, Ramage et 
al. 2006; Achim, Adame et al. 2009). Interestingly, while increased accumulation of amyloid 
precursor protein (APP) was observed in the brains of HIV-infected individuals, the 
presence of phospho-Tau and A were not demonstrated before the implementation of 
cART. Among the factors that may contribute to this shift are increased life span and 
prolonged neuroinflammation. It is established that risk of developing Alzheimer Disease 
(AD) increases with age. In addition, prolonged and/or uncontrolled neuroinflammation 
due to the emergence of new co-morbidities, adjustments in the cART regimens, and direct 
and indirect cART-related neurotoxicity can further exacerbate the neuropathological 
changes that classically occur in the aging brain.  
Both HAND and AD brains show increases in markers of neuroinflammation, oxidative 
stress, and endoplasmic reticulum stress (Lindl, Akay et al. 2007). Interestingly, several in 
vitro and in vivo studies have shown that ARVs can lead to cellular toxicity via oxidative 
stress and endoplasmic reticulum stress (Zhou, Gurley et al. 2006; Gavilan, Pintado et al. 
2009; Salminen, Kauppinen et al. 2009). Interestingly, these aforementioned stress pathways 
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have been shown to increase A secretion both in vitro and in vivo (Velliquette, O'Connor et 
al. 2005; O'Connor, Sadleir et al. 2008). Thus, age-related changes might be partially due to 
cART-related amyloidogenic processes, and the possible contributions of cART to these age-
related changes need to be studied while establishing regimens with high CNS 
concentrations.  
9. Adjunctive therapies 
In addition to the utilization of the CPE scoring system, alternative delivery methods such 
as nanoparticle delivery are being explored. Further, adjunctive therapies are currently 
being studied for their efficiency in alleviating neuroinflammation, and decreasing neuronal 
damage and death. While the initial data obtained from these studies suggest limited 
success, the results are encouraging and constitute a newly expending field in the 
management of HAND.  
9.1 Anti-excitotoxicity agents 
The excitotoxins, such as glutamate and quinolinic acid that accumulate as a result of 
activated and/or infected macrophages and astrocytes cause direct neuronal dysfunction 
via activation of the NMDA receptor, as mentioned previously(O'Donnell, Agrawal et al. 
2006; Lindl, Marks et al. 2010). Thus, memantine, an NMDA receptor antagonist that is 
approved for use in AD (Lipton and Chen 2004) is explored for its neuroprotective effects in 
HAND (Schifitto, Navia et al. 2007). Clinical trials so far report that memantine appears to 
be associated with few side effects, with favorable tolerance. Further, patients that received 
memantine showed improved neurocognitive functions. Given that memantine has shown 
benefits in patients with AD, it emerges as an attractive treatment option in a patient 
population that increasingly consists of aging patients. 
9.2 Anti-oxidants 
Oxidative stress, as mentioned before, is a major component of HIV-induced 
neuroinflammation. The increases in 4-HNE, protein carbonyls, long-chain sphingomyelins 
and ceramides are still observed in the presence of cART (Haughey, Cutler et al. 2004; 
Sacktor, Haughey et al. 2004). Use of illicit drugs and ethanol can induce oxidative stress, 
exacerbating the accumulation of oxidative products, and ARVs might contribute to this 
process. Thus, antioxidants were among the first to be tested as adjuncts to ARVs. Selegiline 
is one such antioxidant that was tested in several small clinical trials (Sacktor, Schifitto et al. 
2000; Schifitto, Zhang et al. 2007). While initial studies conducted in patients receiving 
selegiline and NRTIs showed slight improvement in cognitive functions, a more 
comprehensive study that enrolled patients who received cART reported that neither the 
CSF and neuroimaging markers of oxidative stress nor cognitive and functional deficits   
improved with selegiline over a 24 week period (Schifitto, Yiannoutsos et al. 2009). One 
caveat of this study is its small number of patients, while a second caveat is the lack of 
stratification of patients according to the CPE scores. Thus, future studies that will take CPE 
scores of the cART regimens into account are necessary to better assess the efficacy of 
selegiline. This approach of utilizing antioxidants will be beneficial at multiple levels, such 
as virus-related direct and indirect neurotoxicity, ARV-related oxidative changes in the 
CNS, and alcohol and illicit drug-induced oxidative responses.  
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9.3 Anti-inflammatory agents 
The neuroinflammation in the brains of HIV-infected patients are partially due to the 
activation of macrophages in response to HIV, or co-morbid conditions such as chronic 
alcohol and illicit drug use. In an attempt to resolve the persistent neuroinflammation, 
adjunctive agents to alleviate the inflammatory component of HAND are currently sought. 
One such agent is minocycline, a tetracycline antibiotic with both neuroprotective and anti-
inflammatory effects. Its efficacy has been shown in models of traumatic and ischemic brain 
injury, and other neurodegenerative diseases such as AD and multiple sclerosis (Chen, Ona 
et al. 2000; Du, Ma et al. 2001; Van Den Bosch, Tilkin et al. 2002; Metz, Zhang et al. 2004). 
Further, it has been shown to be effective in limiting HIV replication in vitro and its close 
relative simian immunodeficiency virus (SIV) in vivo (Zink, Uhrlaub et al. 2005). Further, 
neuroinflammation markers in the CNS in the animal model of SIV encephalitis were 
decreased with minocycline administration. Currently, clinical trials are being conducted to 
assess its potential. In summary, its favorable safety profile, ease of administration and 
efficient BBB permeability makes it a viable adjunctive agent.  
10. Conclusion 
One of the paradoxical outcomes of  cART is the persistence of HAND despite successful 
CNS viral control. Moreover, there seems to be a shift from overt dementia to more subtle 
presentations of neurocognitive impairment. Probable cART-related neuronal perturbations 
might contribute, and even precipitate, some of these changes in the chronic course of 
HAND, considering that cART regimens  with higher CPE scores are prescribed in cases of 
higher or uncontrollable viral burden. However, the data regarding the impact of co-
morbidities and possible cART-related side effects on CPE scores and the success of cART 
on HAND need to be expanded, given the ever-expending repertoire of ARVs and the 
patient-tailored, dynamic cART regimens in a multiple-system therapy management to 
ensure more successful outcomes of cART. The information gained from such studies will 
help physicians to determine the most efficient cART regimens with minimal CNS side 
effects, and further help design and determine adjunctive therapeuticals in the management 
of CNS perturbations in HIV-infected patients on long-term cART.  
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